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Schizophrenia patients exhibit a decreased ability to detect change in their auditory environ-
ment as measured by auditory event-related potentials (ERP) such as mismatch negativity.
This deficit has been linked to abnormal NMDA neurotransmission since, among other
observations, non-selective channel blockers of NMDA reliably diminish automatic deviance
detection in human subjects as well as in animal models. Recent molecular and functional
evidence links NR2B receptor subtype to aberrant NMDA transmission in schizophrenia.
However, it is unknown if NR2B receptors participate in pre-attentive deviance detec-
tion. We recorded ERP from the vertex of freely behaving rats in response to frequency
mismatch protocols. We saw a robust increase in N1 response to deviants compared
to standard as well as control stimuli indicating true deviance detection. Moreover, the
increased negativity was highly sensitive to deviant probability. Next, we tested the effect
of a non-selective NMDA channel blocker (ketamine, 30 mg/kg) and a highly selective
NR2B antagonist, CP-101,606 (10 or 30 mg/kg) on deviance detection. Ketamine attenu-
ated deviance mainly by increasing the amplitude of the standard ERP. Amplitude and/or
latency of several ERP components were also markedly affected. In contrast, CP-101,606
robustly and dose-dependently inhibited the deviant’s N1 amplitude, and as a consequence,
completely abolished deviance detection. No other ERPs or components were affected.
Thus, we report first evidence that NR2B receptors robustly participate in processes of
automatic deviance detection in a rodent model. Lastly, our model demonstrates a path
forward to test specific pharmacological hypotheses using translational endpoints relevant
to aberrant sensory processing in schizophrenia.
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INTRODUCTION
While recording event-related potentials (ERPs), when a stream of
identical stimuli are interrupted occasionally by an atypical stim-
ulus, the so-called odd ball, an enhanced negativity to the odd ball
or deviant is observed from fronto-central regions of the scalp-
recorded clinical electroencephalogram. This response is called
the mismatch negativity (MMN) and has been recognized as a pre-
attentive neurocognitive mechanism for change detection in the
environment (1–3). Not surprisingly, an ability to rapidly detect
change is evolutionarily conserved and can be detected across a
variety of species in addition to primates (4–7). Key generators for
auditory mismatch-related negativity have been found within the
primary and secondary auditory cortex with additional sources in
frontal and parietal cortical regions (8–13). Although MMN is per-
haps the best characterized pre-attentive mechanism for deviance
detection that manifests about 100–200 ms after stimulus presen-
tation, it is not the only mechanism for automatic change detection
(1, 14). It is now known that there is neural activity in anatomi-
cal structures along the sensory processing hierarchy involved in
change detection, some apparent as early as 30 ms after stimulus
presentation (15).
Mismatch negativity has been shown to be disrupted in a
variety of mental disorders including schizophrenia, autism, and
dementias (16, 17) and constitutes a convenient measure to eval-
uate neurophysiological function especially because it does not
need engagement from the subjects in terms of participation or
motivation to complete the test – an obvious advantage when
studying psychiatric or neurologically challenged subjects. These
characteristics also make it an attractive model for translation
into preclinical species where apart from studying the neuro-
physiological mechanisms and neural circuits more intensively,
therapeutic hypotheses can be tested to develop potential new
remedies (6, 7, 18).
While mismatch-like deviance detection has been demon-
strated in multiple species, such data from the most commonly
used laboratory species, i.e., rodents has been controversial and
conflicting. In general, when deviance detection was investigated
at the single-unit level or at the local field potential within the
primary auditory cortex, the results have not been encouraging in
that a clear electrophysiological substrate for deviance could not be
established (19, 20). On the other hand, epidural macroelectrode
recordings have generally found evidence for true deviance (4, 21–
23), suggesting that the neural sources may be distributed more
widely (7). Previously, robust deviance detection was shown in
anesthetized Guinea pigs from vertex ERPs but not from the tem-
poral cortex, which is the location for primary cortical processing
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(24, 25). These authors concluded that there are parallel auditory
pathways, and in Guinea pig, the temporal lemniscal stream was
not contributing to deviance detection. Rather, the midline struc-
tures (with input from caudomedial thalamic nucleus) projecting
to multisensory cortical regions below vertex were involved. How-
ever, it is not known if the vertex potentials in rats, which represent
a non-lemniscal processing stream (26, 27), also model deviance
detection.
NMDA receptors have been implicated in the generation of
mismatch negativity. Local application of NMDA antagonists like
PCP disrupts MMN in monkey auditory cortex in a layer-specific
manner (28). Several clinical reports indicate a disruption of
MMN in the presence of a non-selective antagonist like keta-
mine (29–33). Indeed, MMN has been argued as an index of
NMDA receptor dysfunction in schizophrenia in part based on
these findings (28, 32). However, NMDA receptors are heterote-
tramers made of two NR1 and two NR2 subunits with considerable
heterogeneity in expression and distribution within the brain (34,
35). Non-selective cation channel blockers disrupt all NMDA neu-
rotransmission irrespective of subunit composition. Thus, as phar-
macological tools, they have limited utility and cannot decipher
the relative contribution of specific subunits to deviance detec-
tion. While selective ligands are not available for all of the extant
NMDA subunits, highly selective NR2B ligands have been avail-
able for sometime making it possible to test their role in deviance
detection (36, 37). Moreover, although the contribution of NR2B
receptor to deviance detection has not been investigated, several
recent reports have indicated robust participation of NR2B recep-
tors in mediating higher cognitive functions such as behavioral
flexibility in rodents (38–40) and working memory in primates
(41), using tasks that engage medial prefrontal cortex. Interest-
ingly, medial prefrontal cortex has been implicated in auditory
deviance detection (42, 43) and MMN deficits in schizophrenia
patients are explained in the context of selective decrease in gray
matter volume in prefrontal and temporal regions of the brain
and their aberrant mutual connectivity (44–46). In addition to
deviance detection, distinct cortical ERP components such as the
P1–N1–P2 complex represent cortical registration of auditory sen-
sory input (47). These components, especially the N1 and P2,
unlike the early evoked potentials such as the brain-stem responses,
can be modulated by endogenous factors such as attention (48,
49) and are often also reported to be aberrant in schizophre-
nia patients (50–52). However, there is incomplete understanding
of how such observations are modeled by NMDA antagonists.
Rodent ERP components like N1, although not identical to their
human namesake in every respect, nevertheless share important
features, are frequently modulated in similar ways and are regarded
as homologs (53, 54). For example, non-selective NMDA channel
blockers such as ketamine have been shown to modulate the N1
response in healthy controls (33, 55) as well as in rodents (56, 57).
However, there are no published data that examine NR2B effects
on these ERP components.
In the following report, we first tested if there was reliable and
true deviance detection to simple auditory tones in the vertex
potentials of conscious rats. We then tested a single odd-ball pro-
tocol and characterized the effects of two different NMDA channel
modulators at multiple time points after dosing. Additionally, we
also determined the effect of these drugs on three individual ERP
components: P1, N1, and P2, elicited in response to frequent and
infrequent tones. Effects on quantitative EEG (qEEG) parameters
30 min after drug administration were also evaluated. Lastly, brain
samples were collected from a satellite colony of rats at a designated
time point after treatment and processed to estimate the degree of
NR2B receptor engagement using ex vivo occupancy technique.
MATERIALS AND METHODS
SURGERY
All experimental procedures were approved by the Bristol Myers
Squibb Animal Care and Use Committee. Sixteen adult male
Sprague-Dawley rats were anesthetized with isoflurane and
implanted with epidural screw electrodes at the following coor-
dinates (frontal; 6 mm anterior to bregma and 1 mm lateral to
midline; vertex, 5.5 mm caudal to bregma and 1 mm lateral to mid-
line; above auditory cortex, 4.8 mm caudal to bregma and 6 mm
lateral to midline). Access to the electrodes was through a plastic
multi-channel pedestal (Plastics One, Roanoke, VA, USA) fixed on
the skull at the time of the surgery. Post-implantation, the rats were
housed singly in shoe box cages and had unrestricted access to food
and water. The current study used recordings from frontal and ver-
tex leads only. Twelve of the 16 rats used were littermate controls
for a neonatal treatment protocol and as such received once a day
sterile saline injections on postnatal days 9–11. These and other
rats were not used in any other study before electrode implanta-
tion and were thoroughly acclimated to the recording boxes and
the recording tethers in the presence of brief auditory tones similar
to what was used in the current study. The approximate age of the
rats was 10 months at the time of the study.
EEG RECORDING
For EEG recordings, rats were brought to the laboratory in their
home cages and placed individually in sound attenuated record-
ing boxes equipped with a video camera, a house speaker, and
a shielded light-weight cable attached to a commutator (Plastics
One, Roanoke,VA, USA). Using the plastic head mounts, the cables
were attached for continuous EEG recording while permitting free
access to explore within the cage. For the pharmacological study,
rats were first treated as per design and then placed inside the
boxes. Recordings began as early as 10 or 30 min after treatment
(see below).
ERP PROTOCOLS
In order to first determine if there was deviance detection, rats
were subjected to the following three ERP protocols run as part of
one recording session. In the first protocol, 50 ms tones of 1.0 kHz
(90% probability), or 1.5 kHz (deviant; 10% probability) were pre-
sented in a random order while frames of EEG beginning 100 ms
before tone onset and 250 ms after onset were sampled at a 2 kHz
rate. The interstimulus interval (ISI) was fixed at 351 ms. In a
second protocol, the frequencies were flipped to make 1 kHz as
the infrequent stimulus (10%) and 1.5 kHz as the frequent stim-
ulus (standard; 90%). Lastly, a third protocol was used where
10 different frequency tones including a 1.5 kHz tone (control)
were presented randomly at a 10% probability each with the same
ISI as before. Two difference waves were generated for each sub-
ject: by subtracting the averaged ERP to standard (1.5 kHz; 90%
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probability, protocol 2) from that of the deviant (1.5 kHz; 10%
probability, protocol 1); and by subtracting the averaged ERP to
control (1.5 kHz; 10% probability, protocol 3) from that of the
deviant. To test whether the deviance was sensitive to the probabil-
ity of the odd ball, protocols were tested also at 33 and 50% deviant
probability. This was done on a different test session, several days
after the first testing.
PHARMACOLOGICAL TESTING
The experimental protocol used to study the effect of the NMDA
antagonists on deviance detection is illustrated in Figure 3. Sub-
jects were administered with vehicle (saline, sc) or drug (ketamine
30 mpk, ip; CP-101,606, 10 or 30 mpk sc in a cross-over design) and
placed inside recording boxes. ERP protocols were run at 30 min
post-dosing and 60 min post-dosing after each treatment. Addi-
tionally, a 10 min time point was included for vehicle and ketamine
treatments only, to accommodate ketamine’s rapid onset of action.
The 30 min test period was preceded by a 5 min free-running EEG
and video recording to evaluate if the treatments had any effect
on the EEG measure itself as determined by qEEG. Only ERP
protocols 1 and 2 were run in this phase. Thus, there was only
one difference wave generated (deviant-standard). Ketamine was
sourced as the injectible drug Ketaset (Fort Dodge, IA, USA). CP-
101,606 was synthesized in-house by BMS chemists. Free base mass
was used for all dose calculations.
EVOKED RESPONSE POTENTIALS
Single trial data were baseline corrected using the first 99 ms and
low-pass filtered using a second order Butterworth IIR filter with
a 30 Hz cutoff. The filtered individual trials were further visually
evaluated to isolate traces that showed extreme movement-related
fluctuations (typically, >150µV but this threshold was tailored
based on inspection of the individual ERPs). No more than 15% of
the 1000 frames per subject were identified as unsuitable for analy-
sis and excluded. With the remaining artifact free traces, averaged
ERPs were generated for standard and deviant stimuli as described
above.
DEVIANCE COMPUTATION
Examination of the grand average ERP traces from the three pro-
tocols outlined above indicated enhanced negativity around the
N1 peak (Figure 2) in the deviant ERP relative to the standard and
the control ERP. Based on this, we computed area under the curve
of the difference waves (deviant–standard and deviant–control)
in four regions; 30–60 ms, the region encompassing the enhanced
negativity and three other contiguous regions (−30 to 0, 0–30, and
60–90 ms) with zero time defined as the onset of the auditory tone.
These areas were then compared to a hypothetical zero value using
a two-tailed one-sample t -test to determine statistical significance
using an adjusted p-value to account for multiple comparisons
(<0.0125; Graphpad Prism 5.01). Consistent positive or negative
deflection of the difference wave across subjects in this measure
will reflect as a significant difference from zero. Moreover, we chose
to use AUC rather than peak and used all available artifact free trials
to construct deviant (~85), standard (~765), and control (~85).
Doing this allowed us to take advantage of the statistical power
inherent in a larger sample of standard ERP while avoiding a bias
associated with an extreme measure such as the peak amplitude
that may be distorted by unequal trials (58).
ERP COMPONENT MEASUREMENT
ERP components (P1–N1–P2) were identified from averaged trace
for each subject using an automated peak/trough detection fea-
ture (Signal 4.10, CED, UK) with close manual supervision. To
do this, the temporal bounds for ERP components were surveyed
first using the grand average of 16 subjects for each treatment
condition and at each time point. These bounds served as a guide
for automatic peak/trough determination for each animal in a
treatment and time-specific manner. While ERP components were
clearly defined under most conditions, this was not the case for a
few subjects immediately after ketamine (10 min). In such cases,
the highest amplitude within the time range was taken. Once the
peak was determined, mean amplitude in microvolts over a 10 ms
period centered on it was tabulated along with the latency. A one-
way ANOVA with repeated measures followed by Bonferroni’s
post-tests or Student’s t -test was used to determine significant
effects.
To examine treatment effects, AUC30–60 ms from multiple time
points were compared between vehicle treatment and ketamine
on one hand and vehicle and CP-101,606 (10 and 30 mpk) on
the other, using two-way ANOVAs with repeated measures, using
treatment as one factor and time of the ERP sampling as the
second factor (Graphpad Prism 5.01). Detection of statistical sig-
nificance was followed by Bonferroni post-tests between vehicle
and drug treatments at designated times. A p< 0.05 (unless oth-
erwise stated) was deemed to be statistically significant. To further
characterize the effect of NMDA antagonists on ERPs, we looked at
mean N1 amplitude of standards and deviants under all treatment
conditions as outlined above.
FREE-RUNNING EEG
Thirty seconds of EEG data were chosen from each rat for Fourier
analysis while reviewing the associated and time-locked video.
Care was taken to choose an EEG segment that excluded slow wave
activity to control for vigilance state as well as gross movement-
related artifacts. The EEG segments were then Fourier transformed
for absolute and relative power in the conventional frequency
bands using a Hanning window to taper with 50% overlap between
data blocks and an FFT block size of 1024, yielding a resolution of
0.976 Hz. Absolute and relative signal power in frequency bands
(delta, 0.5–4 Hz; theta, 4–9 Hz; alpha, 9–13 Hz; beta 1, 13–19 Hz;
beta 2, 20–30 Hz; gamma 1, 30–55 Hz; gamma 2, 55–100 Hz) were
computed and compared between vehicle and treatments using a
two-way ANOVA with treatment and frequency as the two factors.
Significant treatment or frequency effects were followed-up by
Bonferroni post-tests, which compared individual power bands
between vehicle and drug treatments (GraphpadPrism 5.1). A
p< 0.05 was deemed to be statistically significant.
EX VIVO RADIOLIGAND BINDING FOR NR2B OCCUPANCY
Rats were administered subcutaneously with CP-101,606 at 10 and
30 mg/kg [vehicle: acidified water (pH 4)]. Sixty minutes post-
dose, the rats were killed and the forebrain tissues (after removal
of the cerebellum and brainstem) were rapidly frozen in chilled
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isopentane and stored at−80°C until needed. On the day of occu-
pancy assessment, the brain tissues were thawed and homogenized
in an ice-cold homogenization buffer containing 50 mM KH2PO4,
1 mM ethylenediaminetetraacetic acid (EDTA), 0.005% Triton-
X, 1:1000 dilution of Sigma protease inhibitor 3843 (pH= 7.4).
The brain tissue concentration was 115 mg/ml buffer. In a 96-well
plate, 23 mg of tissue (92 mg/ml) was incubated at 4°C for 5 min
in 5 mM Tris–HCl (pH= 7.4) containing 5.5 nM [3H]RO25-6981,
a highly potent and selective NR2B antagonist (59). [3H]RO25-
6981 was synthesized by the Radiosynthesis Group in Bristol Myers
Squibb. Non-specific binding was defined by inclusion of 10µM
RO25-6981. At the end of the incubation period, the reactions
were stopped by filtration through FPXLR-196 filters (Brandel,
Gaithersburg, MD, USA) that had been soaked in 0.5% poly-
ethyleneimine for 1 h at 4°C. The filters were washed with ice-
cold assay solution and the radioactivity was measured using a
Wallac Microbeta liquid scintillation counter (Perkin Elmer Life
Sciences, Boston, MA, USA). The specific binding to NR2B recep-
tors was calculated by subtracting the value of the non-specific
binding from that of the total binding in each sample. The per-
cent occupancy was calculated as (1−specific binding in drug
treated/specific binding in vehicle treated)× 100%.
DRUGS
Vehicle used in these studies was acidified sterile water for injec-
tion adjusted to a pH of 4.0 and administered subcutaneously.
CP-101,606 was synthesized by BMS chemists in-house and was
dissolved in pH 4.0 sterile water for injection before sc admin-
istration. Ketamine HCl was purchased in its marketed form
(Ketaset, Fort Dodge, NY, USA) and was administered through
the intraperitoneal route.
RESULTS
ERP TO AUDITORY TONES
An overlay of grand averaged ERPs from 16 subjects in response
to a 1.5 kHz tone delivered as a standard, control, or deviant are
shown in Figure 1 (left panel). The grand averaged ERPs showed
a prominent positive, negative, and positive components identi-
fied as P1, N1, and P2, respectively. The grand averaged difference
waves were obtained by subtracting the standard or the control
ERP from that of the deviant ERP and displayed in Figure 1 (right
panel). The two difference waves showed a similar pattern of a
distinct negative peak around 50 ms after stimulus onset. Con-
sequently, areas under the curve were computed for the visually
identified region of negativity 30–60 ms post-stimulus onset for
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FIGURE 1 | Left panel, overlay of standard, deviant, and control ERPs
averaged from 16 rats with ERP components identified. Note prominent
increased negativity under deviant condition. Right panel, difference waves
(deviant–standard and deviant–control) indicating a prominent negativity in the
region of 30–60 ms after stimulus onset. Only 30–60 ms region was
significant (Bonferroni corrected P < 0.0125) compared to contiguous 30 ms
areas (−30 to 0, 0–30, and 60–90 ms). Tone onset was defined as time 0 and
is marked by a vertical bar in this and all other figures that show ERP traces.
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FIGURE 2 |Top panel, AUC30–60 ms areas from difference waves show robust
significance against a hypothetical zero value (Bonferroni corrected
P < 0.0125). Bottom panel, AUC30–60 ms was robustly sensitive to deviant
probability.
both difference waves. These measures showed a robust deviance
from zero (Figure 2, top panel) using a corrected p-value (0.0125)
while no other contiguous bands of area, i.e.,−30 to 0 ms; 0–30 ms;
60–90 ms showed any significant deviance, positive or negative,
from zero (data not shown). Significantly, there was no difference
between the 30 and 60 ms areas generated by the two difference
waves; that is, deviant–standard and deviant–control generated
similar negativity. Increasing odd-ball probability from 10 to 33%
or higher resulted in the elimination of the deviance from both
the difference waves (Figure 2, bottom panel). Since the peak
negativity in the difference waves was coincidental with the N1
response, we hypothesized that it is being driven by an increased
N1 in the deviant waveform. We, therefore, tested the correla-
tion between the AUC30–60 ms of the respective difference waves
with that of N1 amplitude difference between standard or control
and deviant and found robust and highly significant correlations
(r2≥ 0.89; p< 0.0001 for both sets of data). The mean amplitude
and latency of each of the three ERP components are summarized
in Table 1. One-way ANOVA analysis showed robust effects on P1
(and N1) amplitudes depending on whether the ERP components
are derived from a deviant or a standard/control ERP. Subsequent
Bonferroni post hoc tests established a significant reduction in P1
(and an enhancement in N1) of the deviant waveform, compared
to the standard and the control. No such difference was noted
0 min 10 min 30 min 60 min
Treatments
Vehicle (saline; sc)
Ketamine (30 mpk, ip)
CP101606 (10, 30 mpk, sc)
ERP 
(Veh and Ket only)
qEEG
ERP
(all groups)
ERP
(all groups)
FIGURE 3 | Schematic indicates protocol timeline. Treatments were
made in a randomized cross-over design on 16 subjects at time zero. EEG
was collected at three time points post-dosing.
for the P2 response. Lastly, component latencies were unaffected
across the three conditions (Table 1).
EFFECT OF NMDA ANTAGONISTS ON DEVIANCE DETECTION
The effects of non-selective and selective NMDA blockers on
deviance detection were tested in a cross-over study. These studies
were initiated in the same rats, which showed deviance detection
as above, after a gap of several days. However, to accommodate
testing at multiple time points, we simplified the ERP protocol to
collect only standard and deviant ERPs. Thus, a control condition
was not used in this part of the study.
KETAMINE EFFECTS ON DEVIANCE DETECTION
Grand averaged ERPs to standard, deviant, and the difference
wave are shown overlaid for the 10 min time point after vehicle
or ketamine treatment (Figure 4) and indicate a sharply defined
difference wave after vehicle only. Butterfly plots of individual
difference waves 10 min after treatment confirm this difference
(Figure 5) and indicate a lack of temporally consistent pat-
tern of negativity across 16 subjects following ketamine dosing.
Deviance computed as AUC30–60 ms across three time points is
shown in Figure 6 (top panel). A robustly significant treatment
effect [F(1)= 8.44; P = 0.0068] but no significant time or treat-
ment× time interaction was noted. While mean AUC30–60 ms mea-
sure was consistently lower under ketamine vs. vehicle, Bonferroni
post-tests found the difference at individual time points to be not
significant (P > 0.05). Since N1 components were visibly delayed
under ketamine treatment (Figure 4), it is possible that we were
underestimating the deviance by using the 30–60 ms time window
for the AUC determination. To address this, we measured mean
N1 amplitude of standard and deviant under both treatments for
each subject as outlined in the Section “Materials and Methods”.
These data are summarized in Figure 7. As expected, under vehicle
condition (Figure 7, top panel) there was a robust treatment effect
[F(1)= 27.85; P < 0.0001] but no treatment or treatment× time
interaction (P > 0.05). Moreover, Bonferroni post-tests showed
significant difference between standard and deviant at all three
time points (Figure 7, top panel). Whereas under ketamine treat-
ment, while there was a significant treatment effect [F(1)= 6.82;
P = 0.012], only the 30 min time point showed a significant dif-
ference (Figure 8, bottom panel). Moreover, there was a small but
significant treatment effect in the form of an overall augmenta-
tion in standard N1 amplitude under ketamine condition when
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Table 1 | ERP component latency and amplitude under three conditions of evocation.
ERP P1 N1 P2
Latency (ms)
(range)
Mean amplitude (µV) Latency (ms)
(range)
Mean amplitude (µV) Latency (ms)
(range)
Mean amplitude (µV)
Standard 28.70±1.66 3.60±1.07* 52.87±2.61 −9.77±1.44* 94.16±2.62 8.39±1.47
Control 32.45±0.97 4.81±1.40** 54.30±2.03 −9.08±1.64** 90.02±4.78 9.23±1.70
Deviant 28.43±2.04 1.12±1.30 52.35±1.80 −13.87±1.86 91.00±2.93 11.07±1.42
One-way ANOVA F (2,15)=7.46; P =0.0023 F (2,15)=6.02; P =0.0063
*/**Indicate significant difference from corresponding deviant (p<0.05/0.01; one-way ANOVA followed by Bonferroni post-tests).
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FIGURE 4 | Overlay of standard (blue), deviant (red), and difference
wave (deviant–standard; green) ERPs approximately 10min after
vehicle or ketamine treatment is shown. Notice a well-defined
negativity in the difference wave 30–60 ms (dashed box) post-stimulus
onset after vehicle treatment only. Also notice a visible delay in N1 after
ketamine treatment.
compared to N1 under vehicle [F(1)= 5.55; P = 0.022] (Table 2).
There were, however, no time or time× treatment effects noted
(P > 0.05) (Table 2). No significant effects were noted on the
deviant N1 ERP amplitude. However, robust treatment effects were
noted on standard as well as deviant N1 latencies (Table 2) in the
form of significant delays. Robust treatment effects were noted on
the P2 component as well; ketamine suppressed and delayed P2
component of standard ERP (Table 3). Deviant P2 component
was suppressed as well but the delay in latency was not signifi-
cant (P > 0.05) (Table 3). Moreover, a significant treatment effect
only was noted on the P1 component of standard ERP where
ketamine suppressed P1 amplitude [F(1)= 5.49; P = 0.023; data
not shown]. Bonferroni post-tests showed no significance between
vehicle and ketamine treatments on P1 at any of the time points.
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FIGURE 5 | Overlay of difference waves after vehicle or ketamine approximately 10 min after treatment. A consistent pattern of negativity is apparent
after vehicle but not after ketamine.
P1 latency was unaffected (data not shown). No significant P1
effects were noted on the deviant ERP (data not shown). Thus
ketamine treatment profoundly altered the amplitude and latency
of multiple ERP components in a time-sensitive fashion.
EFFECT OF SELECTIVE NR2B ANTAGONIST CP-101,606 ON DEVIANCE
DETECTION
An overlay of the standard, deviant, and difference ERPs 60 min
after vehicle or CP-101,606 treatment are shown in Figure 8.
Whereas a robust negativity of the difference wave is appar-
ent in the 30–60 ms period after stimulus onset after vehicle,
there is little negativity under CP-101,606 treatment. To confirm,
AUC30–60 min across two time points (30 and 60 min after dosing)
were compared between vehicle and CP-101,606, using a two-way
ANOVA with repeated measures. A highly significant treatment
effect [F(2)= 11.86; p< 0.0001] but no significant time or treat-
ment× time interaction effects (P > 0.05) were noted. Further,
Bonferroni tests revealed significant difference between vehicle
and CP-101,606 (10 and 30 mpk; p< 0.05 or greater) at every time
point. These results are summarized in Figure 6 (bottom panel).
Although difference waves were clearly affected by the NR2B antag-
onist, to document if this is driven by the drug response to standard
or deviant or both, we looked at mean N1 amplitude of standard
and deviant ERPs under vehicle and CP-101,606 (10 and 30 mpk)
treatments using a two-way ANOVA. Standard ERPs did not differ
in amplitude or latency between treatments (Figure 9, top panel).
On the other hand, a robust treatment effect in the form of an
amplitude reduction was apparent in deviant N1 [F(2)= 6.01;
P = 0.0042]. Bonferroni post-tests showed a robust suppression
of the deviant N1 treated with CP-101,606 (60 min; 30 mpk only)
compared to vehicle response (Figure 9, bottom panel). No treat-
ment effects on latency were noted for either the standard or
the deviant ERPs (data not shown). To test whether any signif-
icant deviance detection under CP-101,606 treatment remained,
we directly compared N1 of the deviant and standard ERPs at
the two time points at both doses using paired t -tests. No sig-
nificant differences were found (data not shown). Interestingly,
at the 30 mpk dose only, there was a trend level significance for
treatment [F(1)= 2.28; P = 0.1008], indicating a trend toward a
smaller deviant relative to the standard. The two remaining ERP
components of the vertex potentials, namely P1 and P2 were also
scrutinized. No treatment effect or time effect or their interaction
was significant across groups, suggesting that these components
were unaffected by CP-101,606 (data not shown).
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FIGURE 6 |Top panel, AUC30–60 ms of difference waves contrasted after
vehicle or ketamine (10 mg/kg, ip) treatment at three time points. Two-way
ANOVA with repeated measures revealed a strong overall treatment effect
[F (1)=8.44; P =0.0068]. Bottom panel, AUC30–60 ms values contrasted after
vehicle and CP-101,606 (10 or 30 mg/kg, sc) treatment. Two-way ANOVA with
repeated measures showed a strong overall treatment effect [F (2)=11.86;
p<0.0001]. */***Indicates significant difference (P <0.05/P <0.0001)
between vehicle and respective CP-101,606 treatment.
EFFECT OF NON-SELECTIVE AND SELECTIVE BLOCKERS OF NMDA
TRANSMISSION ON QUANTITATIVE EEG MEASURES
Careful EEG review along with synchronized video feed found lit-
tle evidence for sleep under the recording conditions. Moreover,
a dominant theta oscillatory activity, indicative of a wakeful state,
was apparent in all subjects (Figure 10), irrespective of the treat-
ment. As expected, ketamine produced robust increases in absolute
and relative gamma power (Figure 10, left panels). A robust reduc-
tion in relative theta power and a small but significant reduction in
beta 1 relative power were also noted under ketamine. In contrast,
there was an overall increase in theta power under CP-101,606
treatment and a small but significant reduction in beta 1 and 2
relative powers at the 30 mg/kg dose only (Figure 10, top right
panel). No other bands were significantly affected with CP-101,606
treatment.
EX VIVO NR2B OCCUPANCY
A small group of rats were dosed with CP-101,606 (10
and 30 mpk sc; n= 4/dose) and brain samples were col-
lected 60 min post-dosing for ex vivo occupancy. A robust
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FIGURE 7 | Standard and deviant N1 amplitudes compared are shown.
Top panel summarizes post-vehicle responses across three time points.
Two-way ANOVA with repeated measures showed a robust effect of
condition (standard or deviant) on N1 response [F (1)=27.85; P <0.0001].
Bottom panel shows post-ketamine data. A significant condition effect was
noted [F (1)=6.82; P =0.012]. */**Indicate significant treatment effect
(P <0.05/0.01 respectively; Bonferroni post-tests).
occupancy of the NR2B receptor at both doses was noted
(79± 4% at 10 mpk sc and 87± 8% at 30 mpk sc com-
pared to 0± 5% under vehicle condition). These results
are in agreement with rodent ex vivo occupancy of CP-
101,606 reported previously (60, 61). Ketamine occupancy was
not studied.
DISCUSSION
Using two different but complementary approaches to register
deviance, we found reproducible deviance detection in the vertex
ERPs of conscious rats, centered on the N1 response. This effect
was reproducible across multiple sessions and was highly sensitive
to deviant probability. Deviance as defined by deviant–standard
ERP was attenuated by the non-selective NMDA channel blocker
ketamine, validating our approach. On the other hand, the com-
plete disruption of deviance detection by a selective NR2B blocker
suggests that these subunits play a vital and hitherto unexplored
role in automatic deviance detection.
Recent rodent literature on MMN has focused on establishing
whether there is deviance detection in the auditory cortex of rats.
In contrast to some reports in the past that failed to find an MMN-
like response in the primary auditory cortex of anesthetized (19) or
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CP-101606 (10 or 30mg/kg) treatment is shown. Notice a well-defined negativity in the difference wave 30–60 ms post-stimulus onset (dashed box) after
vehicle treatment only.
Table 2 | N1 component latency and amplitude tabulated as standard and deviant across vehicle and ketamine treatments.
N1 only Vehicle Ketamine 30mpk
ERP Latency (ms) Mean amplitude (µV) Latency (ms) Mean amplitude (µV)
Standard10 min 50.2±2.0 6.7±1.2 67.5±2.9*** 8.1±1.8
Standard30 min 54.3±2.2 5.2±1.5 58.3±2.3 8.5±1.7
Standard60 min 52.4±2.4 5.5±2.1 53.4±2.9 8.2±1.9
Two-way ANOVA Treatment; F (1)=15.67; P =0.0003 Treatment; F (1)=5.55; P =0.02;
Treat×Time; F (2)=7.03; P =0.0022 Treat×Time, ns
Time, ns Time, ns
Deviant10 min 46.2±1.7 10.7±1.6 65.4±2.5*** 10.4±3.2
Deviant30 min 50.2±1.8 9.7±1.6 57.3±2.4 14.0±2.6
Deviant60 min 50.8±1.7 11.4±2.5 49.5±3.3 10.4±1.5
Two-way ANOVA Treatment; F (1)=21.8; P <0.0001 Treatment, ns
Treat×Time; F (2)=11.2; P =0.0001 Treat×Time, ns
Time, ns Time, ns
***Indicate p<0.001 (Bonferroni post-tests) when compared to corresponding value under vehicle condition. Note a robust latency delay and an augmentation of
amplitude (standard only) under ketamine.
awake rats (20), many recent rat studies show deviance detection
either as an increase in negativity (22, 62, 63) or an increased pos-
itivity (63), in response to the occasional odd ball by focusing on
epidural ERPs. Moreover, these responses are sensitive to the prob-
ability of deviance and are demonstrable using the rigorous “many
standards” condition first proposed by Jacobsen and Schroeger
(64). The qualitative difference in findings between extracellular
single-unit recordings and local field potentials on one hand and
ERPs on the other appears to be critical (7). Whereas the former
samples from a limited and highly localized group of neurons,
epidural ERPs reflect activity from multiple brain regions, includ-
ing subcortical sources as in the case of midline vertex potentials.
Of course the limitation of an epidural ERP measure is the inability
to unequivocally determine the primary source or generator of the
deviance signal, without extensive further investigation. In the cur-
rent studies, we have focused on midline vertex ERPs that are not
solely dependent on input from the primary auditory cortex (26),
a key source for auditory MMN. Instead, midline ERP responses
are more symmetric across the hemispheres and may reflect activ-
ity from midline subcortical structures that are not a part of the
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Table 3 | N2 component latency and amplitude tabulated as standard and deviant across vehicle and ketamine treatments.
P2 only Vehicle Ketamine 30mpk
ERP Latency (ms) MeanAmplitude (µV) Latency (ms) MeanAmplitude (µV)
Standard10 min 85.6±2.4 9.2±1.4 103.5±6.5** 2.9±1.5***
Standard30 min 89.8±2.2 5.7±1.5 91.4±2.4 3.1±1.1**
Standard60 min 85.6±4.2 5.1±1.5 87.4±3.0 5.7±1.4
Two-way ANOVA Treatment; F (1)=5.48; P =0.023 Treatment; F (1)=11.79; P =0.003
Treat×Time; F (2)=3.2; P =0.0501 Treat×Time; F (2)=6.00; P =0.0049
Time, ns Time, ns
Deviant10 min 88.0±2.4 12.7±1.7 95.1±6.7 3.9±1.9***
Deviant30 min 87.8±2.0 9.6±2.0 88.5±2.8 2.3±1.4**
Deviant60 min 89.0±2.6 9.6±1.8 88.4±2.8 8.5±1.8
Two-way ANOVA Treatment, ns Treatment; F (1)=20.14; P <0.0001
Treat×Time, ns Treat×Time; F (2)=3.43; P =0.041
Time, ns Time, ns
**/***Indicate p<0.01/0.001 (Bonferroni post-tests) when compared to corresponding value under vehicle condition. Note a robust latency delay (standard only) and
a suppression of amplitude under ketamine that wanes over time.
primary lemniscal pathway (24, 25, 65) as well as structures such as
the hippocampus and the anterior cingulate (26). Since deviance
detection may be a fundamental ability required for species sur-
vival, it is not surprising that there are parallel pathways to support
this vital function.
We saw robust separation between deviant and standard or con-
trol beginning about 30 ms post-stimulus onset that peaked within
the following 30 ms. It is possible that the relatively brief tone dura-
tion of 50 ms may have punctuated the negativity as a robust “off”
response at the end of the auditory stimulus was always prominent
culminating in the P2 response. Indeed, it was recently noted that
by prolonging the stimulus duration, the duration of negativity
could be improved (62).
Overall, the only consistent increased negativity we saw hov-
ered around the N1 response and clearly distinguished the larger
deviant response from standard. One criticism about this com-
parison is that since the standard is repeated more frequently than
the deviant, there is a greater neuronal habituation to the standard
stimulus relative to the infrequent deviant and that this does not
represent a true memory trace that is presumed to underlie MMN.
Nevertheless, such a habituation is evidence of a pre-attentive abil-
ity to discriminate a stimulus by means of its context (repetitive or
infrequent). To discount habituation as the only viable mechanism
of deviance detection, however, Jacobsen and Schroeger designed
a control protocol in which multiple stimuli including the deviant
tone are presented randomly at a probability identical to that of the
deviant (64). Since the presentation rate of the stimulus is same
as the deviant, it is expected to have little additional inhibition.
Moreover, because it is presented randomly as part of many other
tones, no necessary context for novelty exists unlike a typical odd
ball, which is presented rarely amidst a stream of identical stan-
dards. Significant difference between a stimulus delivered as part
of a control protocol vs. the same stimulus delivered as an odd
ball is argued to represent true deviance. We saw robust negativity
under standard as well as control conditions suggesting genuine
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FIGURE 9 | Standard and deviant N1 ERP amplitudes after vehicle or
CP-101,606 (10 or 30mg/kg) treatment are shown. Top panel shows
standard N1 amplitudes and bottom panel shows deviant N1 amplitudes.
Notice that only deviants after CP101,606 show apparent dose-dependent
reduction in N1 amplitude. **Indicates P <0.01 (Bonferroni’s post-tests).
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FIGURE 10 | Summary graphs of quantitative EEG parameters analyzed approximately 30min after vehicle or ketamine (30mg/kg, ip), or CP-101,606
(10 or 30mg/kg, sc) treatments. */***Indicate P <0.05/P <0.0001, respectively (Bonferroni post-tests).
deviance detection in the vertex potentials. Moreover, the differ-
ence wave generated by either condition was robustly sensitive to
deviant probability with both 33 and 50% evoking no significant
deviance, suggesting that low deviant probability is critical for
establishing a context of regularity. Within the same group of rats
used in the current studies, the deviance identified as negativity
between 30 and 60 ms after stimulus onset was consistent within
as well as across sessions, allowing us to study the effect of the
NMDA antagonists in a balanced cross-over design that lasted a
few weeks.
Often MMN has been defined operationally as a late negativ-
ity that appears subsequent to the N1 response. Yet in practice,
it is common for the deviance to appear even before the N1 has
peaked and therefore, showing a clear overlap in the deviant N1
recovery trajectory and that of the MMN. This is particularly the
case when there is a robust spectral separation between standard
and deviant tones as in the current study (66). A close examina-
tion of frequency MMN papers that include standard, deviant, and
MMN traces supports this notion of overlap (67–69). Indeed, May
and Tinnen (70) as well as others (71) have argued that MMN is
not distinct from an N1 response modulated by stimulus contin-
gency. We found a strong correlation between AUC30–60 ms and
the amplitude difference between deviant and standard ERPs on
one hand and deviant and control ERPs on the other, establish-
ing that deviance in our studies was being driven by a heightened
N1 response to novel stimuli. Additionally, we saw no consistent
protracted negativity in the difference wave going beyond the N1
time frame. This was unexpected since the midline vertex poten-
tials in Guinea pigs showed robust negativity that not only had an
early onset similar to our finding but also continued throughout
the subsequent ERP trace (24, 25). However, unlike in our data,
they did not see an “off” response that culminated in a P2 wave. In
future studies, it would be interesting to see if the negativity can
be prolonged by prolonging the tone duration as has been shown
recently (62).
In addition to the N1 component being driven by novelty, we
also saw evidence for P1 component in the deviant ERP being sub-
stantially smaller than both standard and control ERPs, suggesting
that even as early as 25 ms after stimulus onset, a deviance was
being registered. Although we have not seen literature evidence
for such early deviance in preclinical ERP recordings, stimulus-
specific adaptation, a putative mechanism for deviance detection,
has been reported as early as 20 ms from stimulus onset in both the
inferior colliculus and the dorsal portion of the medial geniculate,
structures that mediate the non-lemniscal processing of audi-
tory signals (72, 73). Thus, the observed early changes in vertex
recordings may reflect activity from these subcortical structures.
While deviance detection in components earlier than N1 is not
generally reported or discussed typically in the clinical literature on
MMN, a recent report has found evidence for deviance detection
as early as 40 ms in human scalp EEG (74). It has been argued that
N1–MMN–N2b may represent a continuum of deviance detection
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(1). Support for early auditory detection of deviance including
some that precedes MMN has been reviewed recently (14, 75).
Attenuation of MMN by NMDA antagonists has been an
important pharmacological validation ever since it was first
demonstrated in monkeys with PCP (28), and subsequently repli-
cated in multiple species including human, primate, and rodent
(5, 30, 31, 33, 56, 76, 77). Moreover, ketamine, a fast acting,
non-selective NMDA channel blocker with rapid pharmacoki-
netics has been frequently studied for its effects on MMN in
healthy humans. Although a few studies have failed to demonstrate
significant modulation (55, 78, 79), a majority reported diminu-
tion of MMN. In studies where ketamine diminished deviance
response, the basis is often unclear since the difference wave is a
virtual construct materialized by subtracting the standard from
the deviant and frequently standard and deviant ERPs are not
shown.
Given the temporal overlap between standard, deviant, and the
difference wave in our study, we suspected that the N1 com-
ponent could be contributing to the reduced deviance follow-
ing ketamine administration. While ketamine treatment clearly
delayed the appearance of ERP components like N1, the overall
ERP morphology was preserved, allowing component measure-
ments. A significant disinhibition of the standard N1 across three
time points was noted under ketamine (Table 2). Since a stan-
dard ERP is presented many more times than a deviant, it is
under a greater inhibition (i.e., stimulus-specific adaptation). It
is this inhibition that ketamine appears to relieve somewhat. This
effect clearly contributed to the diminished significance between
the deviant and standard ERPs under ketamine. This observa-
tion supports the contention that stimulus-specific adaptation is a
key mechanism underlying deviance detection and non-selective
NMDA blockers interfere with this process. A similar observa-
tion was previously made by Ehrlichman and colleagues using
mouse hippocampal field recordings (56). That ketamine has dis-
inhibitory effects on ERPs is not unprecedented as at least two
clinical studies documented disinhibitory effect of ketamine on
N1 amplitude (33, 55) while using an odd-ball paradigm. Other
reports have described an augmentation of sensory or somatosen-
sory ERPs under ketamine (80, 81), perhaps a result of cortical
glutamate efflux and activation of non-NMDA mediated excita-
tory transmission through AMPA receptors (82). However, others
have found no effect on N1 amplitude in an odd-ball proto-
col (76). We speculate that these differences can be attributed
to variable dose and testing regimens that in turn affect the
degree of NMDA channel blockade obtained in these studies. A
careful temporal characterization of ketamine dose–response on
ERPs generated by an odd-ball protocol could reveal the excita-
tory and inhibitory effects of ketamine on ERPs and reconcile
these differences.
Apart from its amplitude effects, ketamine robustly suppressed
and delayed the latency of ERPs, especially at the first time point
(~10 min post-injection), suggesting a relative slowing of signal
processing and delay in peak synchrony of the neural oscillators
generating the ERP response. Ketamine-induced slowing of ERPs
has been reported both in clinical (30, 83) as well as in experimen-
tal subjects previously (56, 84, 85). Apart from its effects on N1
amplitude and latency, Ketamine impacted other ERP components
as well. Generally, both P1 and P2 components tended to be sup-
pressed relative to vehicle at the 10 and 30 min time points and
recovered by the 60 min time point. Compared to P1, effects on
P2 were more robust. Lastly, ketamine’s effects on qEEG have been
well characterized previously and the current results are in line
with these findings (86, 87). In addition, the dominant power of
theta band is indicative of the strong hippocampal contribution
to the vertex recorded EEG.
Perhaps, the most significant finding of our report was the com-
plete elimination of deviance after treatment with CP-101,606, a
highly selective antagonist of NR2B receptors (88, 89). In con-
trast to ketamine, no significant disinhibition of the standard
N1 response was noted. Instead, there was a dose-dependent
and robust suppression of the deviant N1 response. This sug-
gests that NR2B receptors may be mediating true context-based
deviance detection rather than stimulus-specific adaptation alone.
For example, if NR2B receptors affected adaptation, one would
expect a clear increase in standard ERPs and consequently, no sig-
nificant difference between the less suppressed deviant and the
disinhibited standard. Instead, we saw the opposite; i.e., a sig-
nificant and dose-dependent suppression of the deviant and no
significant disinhibition of the standard ERP. Since a shift in atten-
tion involving frontal cortical regions is believed to be responsible
for enhanced deviant negativity (44, 46, 48, 90), we can speculate
that the NR2B mechanism may be vital for mediating this function
and that selective NR2B antagonists interfere with this process.
Moreover, it has been recently argued that whereas sensory cortices
participate in deviance detection by means of stimulus-specific
adaptation (where neighboring cortical columns are suppressed
from responding to repeated stimuli), connectivity from frontal
regions such as the medial prefrontal cortex to the temporal cor-
tex modulates the gain of this process in an NMDA-dependent
mechanism (31). Consistent with this hypothesis, patients with
localized lesions within the medial prefrontal cortex have poor
deviance detection (42, 43). Moreover, schizophrenia patients as a
group have highly reproducible and stable deficits in MMN even
as they consistently show deficits in cognitive tasks that are driven
by this region such as working memory and executive function
(45, 91–93). Prefrontal cortical neurotransmission is believed to
be especially sensitive to NMDA transmission (94, 95). Recently,
there have been several reports that show that NR2B-based neu-
rotransmission is critical for the optimal function of this region
(39, 41, 96, 97). We speculate that disruption of NR2B neuro-
transmission in prefrontal cortex may contribute to the loss of
deviance detection in NR2B-treated rats. Interestingly, a recent
report showed molecular evidence for potential aberrant traffick-
ing of NR2B receptors, but not NR2A, within cortical layers of
schizophrenia patients (98). The differential effects of CP-101,606
and ketamine on qEEG parameters further highlight how individ-
ual subunit modulation can alter the field response in a way that
is not reflected by non-selective channel blockers.
To conclude, robust deviance detection to pitch changes were
noted in vertex potentials of awake and freely behaving rats. The
deviance detection was diminished by pretreatment with the non-
selective NMDA channel blocker ketamine which disinhibited and
enlarged standard ERP response. On the other hand, the NR2B
selective antagonist CP-101,606 completely abolished deviance
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detection by selectively inhibiting the deviant ERPs. This is the
first demonstration that reducing function of NR2B receptors dis-
rupts the pre-attentive auditory deviance detection mechanism
in rats.
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